Press Releases October 2, 2026 04:05 PM

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics Grants Stock Options and RSUs to New Employees Under Nasdaq Inducement Rule

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
SPRO

Spero Therapeutics, a clinical-stage biopharmaceutical company focused on immunology and inflammation, announced inducement grants totaling 556,000 equity awards (233,000 RSUs and 323,000 stock options) to new employees as part of the Nasdaq Listing Rule 5635(c)(4). These awards are intended as material inducements to attract new talent under the 2019 Inducement Equity Incentive Plan, with standard multi-year vesting schedules linked to continued employment.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SPRO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Spero granted 233,000 restricted stock units (RSUs) and 323,000 stock options to new employees effective October 1, 2026, under the Nasdaq inducement rule.
  • The awards vest over multiple years, incentivizing employee retention and aligning interests with company growth.
  • Spero is advancing novel immunology therapies, including its lead candidate SP001 targeting IgG4-related diseases.
  • Sectors impacted include biopharmaceuticals, biotechnology, and healthcare equity markets.

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero’s Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs) and 323,000 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero’s new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as a material inducement for such individuals entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The shares underlying the options vest as to 25% on the first anniversary of the employee's start date, with the remainder vesting in 36 equal monthly installments thereafter, subject to the employees' continued employment with Spero through the applicable vesting dates. The RSUs will vest in four equal annual installments beginning on the first anniversary of the employee's start date, subject to the employees' continued employment with Spero through the applicable vesting dates. The stock options and the RSUs are subject to the terms and conditions of the 2019 Inducement Plan and the stock option and the RSU agreement covering the grant.

About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological and inflammatory diseases. For more information, visit www.sperotx.com

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
[email protected]

Media Inquiries:
[email protected]


Risks

  • Employee retention risks if new hires leave before vesting periods end, impacting talent acquisition costs.
  • Regulatory risks related to compliance with Nasdaq Listing Rules and potential dilution to existing shareholders.
  • Uncertainty in clinical trial outcomes for experimental therapies like SP001 could affect company valuation and market perception.

More from Press Releases

Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026